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We read with interest the elegant data from (Thanawala et al., 2015) in 
ovalbumin sensitized epinephrine deficient  or wild type mice which suggested 
differential effects of biased signaling with propranolol and nadolol. We were 
particularly intrigued by the observation in epinephrine deficient mice whereby 
there was a disconnect between propranolol and nadolol in restoring the 
asthma phenotype compared to controls. It is tempting to simplistically 
extrapolate these data in mice to what might happen in human subjects with 
asthma in order to explain the negative effects of propranolol on airway hyper-
responsiveness (AHR), reported in two separate placebo controlled double 
blind trials in patients receiving inhaled corticosteroids (ICS), which were 
powered to detect a one doubling dilution difference in the provocative 
concentration of methacholine (n=18) or histamine (n=16) to produce a 20% 
fall in forced expiratory volume in 1s (i.e. the PC20 FEV1 threshold) 
(Anderson et al., 2014; Short et al., 2013). In this regard, in patients with 
persistent asthma, the PC threshold for FEV1 is closely related to PC 
threshold for airway resistance (Short et al., 2015).  
Upon close inspection of the data for methacholine AHR (Thanawala et al., 
2015), the provocative concentration  to induce a 100% increase (PC100 
threshold) in airway resistance was unaltered in wild mice (n=6) treated with 
propranolol in contrast to an increase with nadolol (n=7). The blunting of 
methacholine AHR with nadolol which was statistically significant (P<0.05) 
amounting to approximately a 0.6 doubling dilution shift compared to vehicle 
treated mice (n=10). Such an effect in mice with nadolol on AHR would be 
considered clinically irrelevant in human patients as it less than the minimal 
important difference of one doubling dilution shift in PC threshold. It is 
therefore difficult to extrapolate the magnitude of this effect with nadolol on 
methacholine AHR in mice to what has previously been reported in two 
unblinded studies with nadolol in human asthmatic subjects which amounted 
to an approximate two doubling dilution shift in methacholine PC20, albeit in 
mild intermittent asthmatics who were not taking ICS (Hanania et al., 2010; 
Hanania et al., 2008).  
It is however unclear how the relative mg dose per body weight of propranolol 
in mice (80-140mg/L in water) equates to that in humans (80mg slow release 
tablet /day). Moreover if propranolol at usual therapeutic doses of 80mg/day 
does indeed confer arrestin independent partial agonist activity at the ERK1/2 
activation pathway in humans then one might expect to see an increase in 
TH2 mediated inflammatory biomarkers. For example in persistent asthmatics 
there was no worsening in eosinophils, eosinophlic cationic protein or exhaled 
breath nitric oxide when oral propranolol 80mg/day was added to a low dose 
of ICS, while a higher dose of ICS in conjunction with oral placebo produced 
further suppression of the same TH2 biomarkers (Anderson et al., 2014). 
Moreover asthma control and disease specific quality of life were also 
unaltered by propranolol (Anderson et al., 2014; Short et al., 2013). 
In order to properly confirm the putative beneficial effects of biased inhibitory 
signaling in mice this will require a placebo controlled trial to demonstrate 
clinically relevant improvements  in methacholine PC20, inflammatory 
markers and asthma control with nadolol on top of existing ICS therapy in 
persistent asthma. The placebo controlled clinical trial (clinicaltrials.gov 
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